<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03848286</url>
  </required_header>
  <id_info>
    <org_study_id>KL167-Ⅱ-05-CTP</org_study_id>
    <nct_id>NCT03848286</nct_id>
  </id_info>
  <brief_title>KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy</brief_title>
  <official_title>An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Recurrent/Metastatic Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to evaluate the efficacy of KL-A167 injection in subjects with&#xD;
      recurrent/metastatic Nasopharyngeal Carcinoma, as measured by Overall Response Rate (ORR) per&#xD;
      the Response Evaluation Criteria in Solid Tumors RECIST Version 1.1&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">February 28, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) assess by Independent Review Committee (IRC)</measure>
    <time_frame>from first patient first visit to 6 month after last patient first visit</time_frame>
    <description>Based on Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR assess by investigators</measure>
    <time_frame>from first patient first visit to 6 month after last patient first visit</time_frame>
    <description>Based on Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) and Immune-related Response Evaluation Criteria In Solid Tumors 1.1 (irRECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>up to approximately 1 year</time_frame>
    <description>PFS as measured in accordance with the Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to approximately 1 year</time_frame>
    <description>Overall Survival is defined as the time from registration to death due to any cause, or censored at date last known alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>from first patient first visit to 6 month after last patient first visit</time_frame>
    <description>Based on Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>up to approximately 1 year</time_frame>
    <description>Based on Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response(TTR)</measure>
    <time_frame>from first patient first visit to 6 month after last patient first visit</time_frame>
    <description>From the date of the first dose of KL-A167 to the time the response criteria are first met</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <condition>Recurrent or Metastatic</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KL-A167 Injection</intervention_name>
    <description>KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years and older&#xD;
&#xD;
          -  Histologically confirmed Recurrent/Metastatic Nasopharyngeal Carcinoma&#xD;
&#xD;
          -  Stage IVb R/M NPC failed from first-line platinum based chemotherapy and second-line&#xD;
             chemotherapy&#xD;
&#xD;
          -  ECOG performance status of 0 or 1&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  Subjects must have measurable disease by CT or MRI per RECIST 1.1 criteria&#xD;
&#xD;
          -  Can provide either a newly obtained or archival tumor tissue sample&#xD;
&#xD;
          -  Subject must have adequate organ functions and meet requirements on laboratory&#xD;
             values.：Count of Blood Cells: absolute neutrophil count (NEUT#) ≥ 1.5 × 10^9 / L;&#xD;
             platelet count (PLT) ≥ 90 × 10^9 / L; hemoglobin content (HGB) ≥ 9.0 g / L; Liver&#xD;
             function: serum total bilirubin (TBIL) ≤ 1.5 × normal upper limit (ULN); alanine&#xD;
             aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN，with the&#xD;
             exception of patients with hepatic metastases (ALT and AST ≤ 5 × ULN) and patients&#xD;
             with hepatic metastases or Gilbert's syndrome (total bilirubin ≤ 3 × ULN)；Renal&#xD;
             function: Creatinine clearance rate（CCR）≥50 mL/min；International normalized ratio&#xD;
             (INR) and Activated partial thromboplastin time (APTT) ≤ 1.5 x ULN ；Thyroid function:&#xD;
             thyroid stimulating hormone (TSH), free thyroxine（FT4）and free triiodothyronine(FT3)&#xD;
             in normal ±10% range, hypothyroidism controlled by drug can be included,&#xD;
             hyperthyroidism can not be included&#xD;
&#xD;
          -  Prior chemotherapy, radiotherapy, immunotherapy or investigational therapy (including&#xD;
             Chinese herbal medicine and Chinese patent medicine) used to control cancer including&#xD;
             locoregional treatment must have been completed ≥ 4 weeks before the first dose of&#xD;
             KL-A167(Mitomycin or nitroso must have been completed ≥ 6 weeks), antibody therapy&#xD;
             must have been completed ≥ 12 weeks, and all treatment-related adverse events (except&#xD;
             alopecia) are stable and have either returned to baseline or Grade 0/1&#xD;
&#xD;
          -  Subjects of reproductive potential must be willing to use adequate contraception&#xD;
             during the course of the study and through 6 months after the last dose of study&#xD;
             medication. Female of child bearing potential, a negative serum pregnancy test result&#xD;
             within 72 h before study treatment&#xD;
&#xD;
          -  Subject has voluntarily agreed to participate by giving written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject of locally advanced can receive radical treatment such as surgery, radical&#xD;
             radiotherapy or radical chemotherapy, can not be included&#xD;
&#xD;
          -  Subjects having metastases to central nervous system&#xD;
&#xD;
          -  Has a known additional malignancy before study treatment with the exception of&#xD;
             curatively treated carcinoma in situ of the cervix or breast and/or superficial&#xD;
             bladder cancer and/or gastrointestinal mucosal carcinoma and/or localized prostate&#xD;
             cancer within the last 5 years&#xD;
&#xD;
          -  History of severe hypersensitivity reaction to monoclonal antibodies&#xD;
&#xD;
          -  Prior exposure to any anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody or CAR-T&#xD;
             cell therapy&#xD;
&#xD;
          -  Need the palliative irradiation during the study except for bone metastasis&#xD;
&#xD;
          -  Need the other anticancer therapy during the study&#xD;
&#xD;
          -  Received any anticancer vaccine within 3 months before first dosing&#xD;
&#xD;
          -  Received ASCT within 3 months before first dosing or received Allo-SCT&#xD;
&#xD;
          -  Active infection or an unexplained fever before first dosing&#xD;
&#xD;
          -  Received a systematic antibiotics within 1 week of signing informed consent&#xD;
&#xD;
          -  Subjects with any active autoimmune disease or history of autoimmune disease&#xD;
&#xD;
          -  Conditions requiring systemic treatment with either corticosteroids (&gt; 10 mg daily&#xD;
             Prednisone equivalent) or other immunosuppressive medications within 14 days of first&#xD;
             dose of KL-A167&#xD;
&#xD;
          -  Serious medical diseases, ex Suffering from heart failure (New York Heart Association&#xD;
             standard III or IV), ischemic heart disease (such as myocardial infarction or angina),&#xD;
             uncontrolled diabetes(fasting blood glucose≥10 mmol/L), uncontrolled high blood&#xD;
             pressure(Systolic&gt; 150 mmHg and / or diastolic&gt; 100 mmHg), LVEF&lt;50%&#xD;
&#xD;
          -  QTc&gt;450 msec(male) or 470 msec(female)&#xD;
&#xD;
          -  Electrocardiogram is abnormal and the researcher consider that KL-A167 has an&#xD;
             additional risk to the subject&#xD;
&#xD;
          -  Known active HBV or HCV infection&#xD;
&#xD;
          -  Known HIV infection&#xD;
&#xD;
          -  Has history of interstitial lung disease or non-infectious pneumonitis. Subjects with&#xD;
             prior drug-induced or radiation-induced pneumonitis who are asymptomatic are eligible&#xD;
&#xD;
          -  Known active pulmonary tuberculosis or has history of tuberculosis infection and are&#xD;
             not controlled after treatment&#xD;
&#xD;
          -  Has history of AE greater than or equal to level 3 related with immune system during&#xD;
             the Immunotherapy&#xD;
&#xD;
          -  Received a live vaccine within 4 weeks of the first dose of KL-A167 or plan to receive&#xD;
             live vaccine during study period&#xD;
&#xD;
          -  Known neurological or psychiatric diseases&#xD;
&#xD;
          -  Ongoing alcohol or drug abuse&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Participation in another clinical trial within the past 1 month&#xD;
&#xD;
          -  According to the investigator, other conditions that affect efficacy or safety of the&#xD;
             research&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dawei Wu</last_name>
    <phone>010-87788268</phone>
    <email>wumingshi-117@163.com</email>
  </overall_contact>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 12, 2019</study_first_submitted>
  <study_first_submitted_qc>February 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2019</study_first_posted>
  <last_update_submitted>February 19, 2019</last_update_submitted>
  <last_update_submitted_qc>February 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nasopharyngeal Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

